NTRA News and Press, Natera Inc. From 10/03/23

Final decision follows multiple previous court rulings in favor of Natera and upholds invalidation of CareDx patents Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that the United States Supreme Court denied CareDx, Inc.’s (NASD...

Lays groundwork for multiple submissions across cancer types, starting with CDx label in bladder cancer Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the submission of the first module of its premarket approval (PMA) application to the U....

2023-10-01 16:02:12 ET Bernstein is bullish on medtech stocks Thermo Fisher, Guardant Health, Revvity and PacBio, but sees further downside for Illumina, according to a new industry note. The investment firm kicked off coverage of the US life science tools and diagnostics sector last we...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced three appointments within its senior leadership team, effective immediately. Solomon Moshkevich has been promoted to president of clinical diagnostics and will lead Natera’s team of general manag...

Prospective study to monitor 600 patients in real time, across all subtypes of breast cancer Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study as part of the I-SPY 2 trial, sponsored and operated by Quantum Leap Healthcare Collaborati...

2023-09-07 05:46:15 ET More on Natera Financial information for Natera Natera: Strong Growth Amidst Profitability Challenges Natera announces $250M common stock offering CareDx wins injunction against Natera in false advertising case For further detai...

Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the pricing of its underwritten public offering of 4,550,000 shares of its common stock at a price to the public of $55.00 per share. Closing of the offering is expected to occur on September 11, 2023, ...

2023-09-06 16:46:21 ET More on Natera Seeking Alpha’s Quant Rating on Natera Historical earnings data for Natera Financial information for Natera Natera: Strong Growth Amidst Profitability Challenges Natera, Inc. 2023 Q2 - Results - Earnings Ca...

Represents third covered indication for Prospera Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that it has received confirmation that its Prospera Lung donor-derived cfDNA (dd-cfDNA) transplant assessment test has met coverage require...

2023-08-15 09:25:20 ET Summary Natera specializes in cfDNA technology, achieving 31.9% revenue growth in Q2 2023 and raising their annual outlook. Despite strong growth, Natera faces challenges with profitability, annual cash burn, and existing debts. Considering growth prospe...